SLC3037

SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases[1].

C29H35N7OS

529.7

CN(CCNC(C1=CC(C2=CSC3=C2N=C(N=C3)NC4=CC=C(C=C4)N5CCN(CC5)CC)=CC=C1)=O)C

NEKs; NOD-like Receptor (NLR)

NEK7; NLRP3

10mM

99.85

DMSO : 200 mg/mL (ultrasonic)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature